<DOC>
	<DOC>NCT02790840</DOC>
	<brief_summary>The purpose of this study is to compare the multiple dose pharmacokinetics (PK) of three AF-219 formulations; to assess the effect of Omeprazole on the multiple dose PK of three AF-219 formulations; and, to assess the safety and tolerability of AF-219.</brief_summary>
	<brief_title>A Multiple-Dose Pharmacokinetics Study of Three AF-219 Formulations</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Be informed of the nature of the study and have provided written informed voluntary consent Be able to speak, read, and understand English; Be healthy males or females, of any race, between 18 and 55 years of age, inclusive; Have a body mass index (BMI) &gt;18.5 and &lt;32.0 kg/m2 and weigh 50 100 kg; Be in good general health with no clinically relevant abnormalities based on the medical history, physical examination, clinical laboratory evaluations (hematology, clinical chemistry, and urinalysis), and 12lead electrocardiogram; Be only nonsmokers or intermittent (social) smokers for at least 5 years, and able to refrain from smoking (or using nicotine) while in confinement; If a female of childbearing potential or not postmenopausal, agree to use 2 forms of acceptable birth control; Be able to communicate effectively with the Investigator and other study center personnel and agree to comply with the study procedures and restrictions Have previously received AF219; Any disease or condition that might affect drug absorption, metabolism, or excretion or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease; Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication; Any past sinus surgery, upper respiratory tract infection within 2 weeks before dosing, or history of hayfever during the time of the year that dosing will be taking place; History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2histamine blockers or proton pump inhibitors within 12 months of Screening; QTcB &gt;450 msec in males or &gt;470 msec in females; Known or suspected hypersensitivity or allergic reaction to any of the components of AF219 or omeprazole capsules; If female, is pregnant or breast feeding, or has a positive pregnancy test predose; Blood loss or blood donation of &gt;550 mL within 90 days or plasma donation &gt;500 mL within 14 days before administration of the first dose of study drug; Chronic use of any systemic medications (other than allowable oral and implanted contraceptives and with the exception of vitamins taken at standard supplement doses); use of a drug therapy (including herbal preparations, e.g., St. John's wort) known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; or use of any medications [prescription or overthecounter (OTC)], including antacids, highdose multivitamins, nutritional supplements, and herbal preparations, within 14 days before the first dose of study drug, unless deemed acceptable by the Investigator and Sponsor; Past or current history or evidence of drug or alcohol abuse, regular use of more than 2 units of alcohol per day (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 40%), use of any recreational soft drugs (e.g., marijuana) within 3 months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year of screening, and/or a positive screen for substances of abuse or alcohol at screening or predose; Ingestion of grapefruit or grapefruit juice within 48 hours before dose administration; Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody; Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication; Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half lives, whichever is longer) before the first dose of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Volunteers</keyword>
</DOC>